Placebobehandlede kvinder havde en forekomst af cystiske forandringer på 1, 9% over 3 år, mens Fablyn- behandlede kvinder havde en forekomst på 20, 4%.
Placebo-treated women had a 1.9% incidence in cystic change over 3 years, whereas the FABLYN-treated women had a 20.4% incidence.